Evidence map›Paper›PMID 39412635›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Pyrimidine metabolism reshapes immune microenvironment and implies poor prognosis in glioma.

Ruoyu Huang, Jingchen Yang, Xuejing Li, Huiyuan Chen, Xing Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruoyu HuangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jingchen YangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuejing LiDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, No. 119 South 4th Ring West Road, Beijing, 100070, People's Republic of China.
Huiyuan ChenDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, No. 119 South 4th Ring West Road, Beijing, 100070, People's Republic of China.
Xing LiuDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, No. 119 South 4th Ring West Road, Beijing, 100070, People's Republic of China. liuxing_bjni@mail.ccmu.edu.cn.ORCID http://orcid.org/0000-0002-5786-2838

Funding

National Natural Science Foundation of China 1902533National Natural Science Foundation of China 82303667
6 · The paper itself

Abstract

backgroundThe metabolic environment of glioma is extremely complex. Pyrimidine metabolism can significantly influence malignant progression of multiple kinds of cancer cells. In this study, we intend to explore the relationship between pyrimidine metabolism and malignant progression of glioma.

methodsWe analyzed two glioma RNA-sequencing databases to construct a pyrimidine metabolism-related risk signature. An individualized prognosis prediction model based on this risk signature was established. Functional analysis and in vitro experiments were conducted to assess the role of pyrimidine metabolism in the tumor-immune microenvironment and malignant progress of gliomas.

resultsThe high-risk group, as predicted by the pyrimidine metabolism-related risk score, showed a tendency toward more malignant entities and poorer survival outcomes. Functional analysis revealed that pyrimidine metabolism significantly regulates the tumor-immune microenvironment. In vitro experiments confirmed that targeting pyrimidine metabolism-related genes can inhibit malignancy of glioma cell.

conclusionIn short, the pyrimidine metabolism-related signature we established could serve as an independent prognostic biomarker in diffuse gliomas and has a close association with regulation of the tumor-immune microenvironment.

Indexed as

Brain NeoplasmsGliomaPyrimidinesTumor MicroenvironmentBiomarkers, TumorCell Line, TumorFemaleHumansMalePrognosisBiomarkers, TumorpyrimidinePyrimidinesGliomaPrognosisPyrimidine metabolismRisk scoreTumor-immune microenvironment

Identifiers

PMID39412635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.